Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients wit...
May 23 2019 - 8:00AM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT) announced today that new data
demonstrating the Afirma® Xpression Atlas test’s ability to detect
gene alterations that may be targeted by new treatments for
medullary thyroid cancer – a rare, but aggressive form of thyroid
cancer – will be presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in
Chicago.
“These data underscore the role that Afirma genomic testing can
play in helping patients with indeterminate thyroid nodules avoid
unnecessary diagnostic surgery, while also helping to inform
treatment decisions for those patients whose nodules are suspicious
for cancer or who have been diagnosed with medullary thyroid cancer
by the Afirma Genomic Sequencing Classifier,” said Bonnie Anderson,
chairman and chief executive officer of Veracyte. “Moreover, our
RNA whole-transcriptome sequencing platform enables us to help
answer a range of important clinical questions – all from the same
minimally invasive patient sample that is used for initial
diagnosis.”
Following are details of the poster presentation:
Title: Genomic Landscape of FNAs Positive for Medullary
Thyroid Cancer and Potential Impact on Systemic Therapy Presenter:
Lori J. Wirth, M.D., Massachusetts General Hospital Date/Time:
Saturday, June 1, 1:15 – 4:15 p.m. CT Location: McCormick Center,
Hall A, Head and Neck Cancer Session Abstract #: 6087 Poster Board
#: 76
About Afirma
The Afirma Genomic Sequencing Classifier (GSC) and Xpression
Atlas provide physicians with a comprehensive solution for a
complex landscape in thyroid nodule diagnosis. The Afirma GSC was
developed with RNA whole-transcriptome sequencing and machine
learning and helps identify patients with benign thyroid nodules
among those with indeterminate cytopathology results in order to
help patients avoid unnecessary diagnostic thyroid surgery. The
Afirma Xpression Atlas provides physicians with genomic alteration
content from the same fine needle aspiration samples that are used
in Afirma GSC testing and may help physicians decide with greater
confidence on the surgical or therapeutic pathway for their
patients. The Afirma Xpression Atlas includes 761 DNA variants and
130 RNA fusion partners in over 500 genes that are associated with
thyroid cancer.
About Veracyte
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company
that improves patient care by providing trustworthy and actionable
answers to challenging clinical questions. The company's products
uniquely combine advanced genomic technology, clinical science and
machine learning to provide answers that give physicians and
patients a clear path forward, informing both diagnosis and
treatment decisions without the need for costly, risky surgeries
that are often unnecessary. Since its founding in 2008,
Veracyte has commercialized five genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and
idiopathic pulmonary fibrosis. Veracyte is based in South San
Francisco, California. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, the ability of
Veracyte’s Afirma Xpression Atlas to help characterize medullary
thyroid cancer, the ability of Veracyte’s Afirma GSC to identify
Hürthle cells, the expected impacts of Veracyte’s collaboration
with Johnson & Johnson in developing interventions for lung
cancer, on Veracyte’s financial and operating results, on the
timing of the commercialization of the Percepta classifier, and on
the size of Veracyte’s addressable market. Forward-looking
statements are neither historical facts nor assurances of future
performance, but are based only on our current beliefs,
expectations and assumptions. These statements involve risks and
uncertainties, which could cause actual results to differ
materially from our predictions, and include, but are not limited
to: our ability to achieve milestones under the collaboration
agreement with Johnson & Johnson; our ability to achieve and
maintain Medicare coverage for our tests; the benefits of our tests
and the applicability of clinical results to actual outcomes; the
laws and regulations applicable to our business, including
potential regulation by the Food and Drug
Administration or other regulatory bodies; our ability to
successfully achieve and maintain adoption of and reimbursement for
our products; the amount by which use of our products are able to
reduce invasive procedures and misdiagnosis, and reduce healthcare
costs; the occurrence and outcomes of clinical studies; and other
risks set forth in our filings with the Securities and
Exchange Commission, including the risks set forth in our quarterly
report on Form 10-Q for the quarter ended March 31, 2018.
These forward-looking statements speak only as of the date hereof
and Veracyte specifically disclaims any obligation to
update these forward-looking statements or reasons why actual
results might differ, whether as a result of new information,
future events or otherwise, except as required by law.
Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are
trademarks of Veracyte, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190523005129/en/
Investor and Media
Contact:Angie McCabeVice President, Investor
Relations & Corporate
Communications650-243-6371angie@veracyte.com
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Sep 2023 to Sep 2024